| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mohamed A Sherif, Jose A Cortes-Briones, Mohini Ranganathan, Patrick D Skosni. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. The European journal of neuroscience. vol 48. issue 8. 2019-11-14. PMID:29247465. |
preclinical and clinical data suggest that the cannabinoid and glutamatergic systems are implicated in the pathophysiology of schizophrenia (sz), the prototypical psychotic disorder. |
2019-11-14 |
2023-08-13 |
Not clear |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Stefan Fritze, Cristina E Topor, Dagmar Koethe, Cathrin Rohlede. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:30022465. |
role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. |
2019-10-10 |
2023-08-13 |
Not clear |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Stefan Fritze, Cristina E Topor, Dagmar Koethe, Cathrin Rohlede. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:30022465. |
since its discovery, multiple clinical and preclinical studies have linked the endocannabinoid system to schizophrenia. |
2019-10-10 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
proteomics and lipidomics in the elucidation of endocannabinoid signaling in healthy and schizophrenia brains. |
2019-09-12 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
additionally, the endocannabinoid signaling network with other non-cannabinoid targets, and the effects of phytocannabinoids increase the complexity to understand their role in schizophrenia and homeostasis conditions. |
2019-09-12 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
herein, the authors review proteomic and lipidomic studies that have been used for analysis of the endocannabinoid system in healthy and schizophrenia function. |
2019-09-12 |
2023-08-13 |
Not clear |
| Maya R Jacobson, Jeremy J Watts, Isabelle Boileau, Junchao Tong, Romina Mizrah. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 3. 2019-08-26. PMID:30635160. |
the most well established finding is the down-regulation of cannabinoid cb1 receptors (cb1r) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia. |
2019-08-26 |
2023-08-13 |
Not clear |
| Inés Ibarra-Lecue, Fuencisla Pilar-Cuéllar, Carolina Muguruza, Eva Florensa-Zanuy, Álvaro Díaz, Leyre Urigüen, Elena Castro, Angel Pazos, Luis F Callad. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochemical pharmacology. vol 157. 2019-07-08. PMID:30026022. |
the present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. |
2019-07-08 |
2023-08-13 |
human |
| Zhiling Guo, Yiu Chung Tse, Ying Zhang, Qiang Sun, Haley A Vecchiarelli, Robert Aukema, Matthew N Hill, Tak Pan Wong, Patricia Boks. Prenatal immune activation potentiates endocannabinoid-related plasticity of inhibitory synapses in the hippocampus of adolescent rat offspring. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 12. 2019-06-12. PMID:30257799. |
the endocannabinoid (ecb) system has been implicated in the pathophysiology of schizophrenia while models of cortical dysfunction postulate an imbalance between neuronal excitation and inhibition in the disorder. |
2019-06-12 |
2023-08-13 |
rat |
| Felipe V Gomes, Jessica R Edelson, David W Volk, Anthony A Grac. Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. Schizophrenia research. vol 201. 2019-05-20. PMID:29705007. |
altered brain cannabinoid 1 receptor mrna expression across postnatal development in the mam model of schizophrenia. |
2019-05-20 |
2023-08-13 |
human |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
familial abnormalities of endocannabinoid signaling in schizophrenia. |
2019-05-14 |
2023-08-13 |
Not clear |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. |
2019-05-14 |
2023-08-13 |
Not clear |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
this is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states. |
2019-05-14 |
2023-08-13 |
Not clear |
| David D Aguilar, Andrea Giuffrida, Daniel J Lodg. Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility. The international journal of neuropsychopharmacology. vol 21. issue 4. 2019-04-29. PMID:29329382. |
adolescent synthetic cannabinoid exposure produces enduring changes in dopamine neuron activity in a rodent model of schizophrenia susceptibility. |
2019-04-29 |
2023-08-13 |
Not clear |
| Pankaj Pandey, Narayan D Chaurasiya, Babu L Tekwani, Robert J Doerkse. Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. Biochemical pharmacology. vol 155. 2019-04-04. PMID:29958841. |
the endocannabinoid system plays an important role in the pathophysiology of various neurological disorders, such as anxiety, depression, neurodegenerative diseases, and schizophrenia; however, little information is available on the coupling of the endocannabinoid system with the monoaminergic systems in the brain. |
2019-04-04 |
2023-08-13 |
human |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
cannabinoids and glial cells: possible mechanism to understand schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
clinical and neurobiological findings have reported the involvement of endocannabinoid signaling in the pathophysiology of schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
in this regard, glial cells express cannabinoid receptors and synthesize endocannabinoids, and cannabinoid drugs affect some functions of these cells that can be implicated in schizophrenia pathobiology. |
2018-12-19 |
2023-08-13 |
Not clear |
| Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi, Franco Dosi. Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules (Basel, Switzerland). vol 23. issue 10. 2018-12-12. PMID:30262735. |
there is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. |
2018-12-12 |
2023-08-13 |
Not clear |
| Huiqiong Deng, Satyajit Mohite, Robert Suchting, David A Nielsen, Olaoluwa O Okusag. Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders. Psychiatry research. vol 261. 2018-11-20. PMID:29329043. |
the purpose of this study was to evaluate the impact of synthetic cannabinoid use at admission on length of stay and doses of antipsychotics at discharge in individuals with bipolar disorder, schizophrenia and other psychotic disorders. |
2018-11-20 |
2023-08-13 |
Not clear |